准分子激光原位角膜磨镶术治疗近视的近期疗效观察

目的：分析探讨准分子激光原位角膜磨镶术治疗近视的近期疗效观察。方法：选取220例（430眼）近视患者作为研究对象,按照患者屈光度数将其分为三组,所有患者均给予准分子激光原位角膜磨镶术治疗,术后随访观察三组患者视力、术后屈光度数改善情况及术后并发症发生情况。结果：220例患者术后视力裸眼视力明显提升,手术前后患者视力水平比较差异有统计学意义（P〈0.05）；三组患者术后随访半年发现A组、B组患者术后视力恢复情况明显优于C组（P〈0.05）。术后A组、B组患者残余屈光度分布情况明显优于C组,组间比较差异有统计学意义（P〈0.05）；430眼术后5眼主诉眩光,1眼欠矫-1.00 D,2眼过矫＋1.50 D,3眼角膜瓣移,4眼高压眼,1眼视网膜脱落,8眼感染急性结膜炎,并未发生其他严重的并发症。结论：对近视患者行准分子激光原位角膜磨镶术治疗具有显著的近期疗效,尤其是12.00 D以下近视患者,有效性与安全性均有保障,准分子激光原位角膜磨镶术可以作为近视临床治疗的选择方式之一。

Recent Efficacy Observation of Excimer Laser in Situ Keratomileusis in Treatment of Short Sight

Objective： To discuss the recent efficacy of excimer laser in situ keratomileusis treatment to short sight.Method： 220 patient （430 eyes） with short sight were selected as objects of this study. They were assigned into three groups according to degrees of refraction. All patients were given excimer laser in situ keratomileusis treatment. We had follow-up to observe vision, improvement of degrees of refraction and occurrence of complications of the three groups after operation.Result： After operation, visual acuity of the 220 patients had an obvious promotion. There were significant differences in visual acuity of patients before and after surgery （P〈0.05）. In the half year’s follow-up of the three groups after surgery, the visual recovery of group A and group B were obviously better than that of group C （P〈0.05）. After surgery, the distribution of residual refractive error in group A and group B was significantly better than that of group C, and the differences were obvious （P〈0.05）. After surgery, among the 430 eyes, there were 5 complained of glare, 1 undercorrection -1.00 D, 2 overcorrection ＋1.50 D, 3 cornea flap shift, 4 high-pressure eye, 1 retinal detachment, 8 acute conjunctivitis infection and no other serious complications occurred.Conclusion： Applying excimer laser in situ keratomileusis treatment to patients of short sight has obvious recent efficacy, especially for those who has short sight below 12.00 D. Efficacy and safety are both guaranteed. Excimer laser in situ keratomileusis can be a choice for clinical treatment of short sight.